Silicone Breast Implant Manufacturers, Breast Implant Helpline

Contact a Female Social Worker Today

*(denotes required field)

Name: *

E-Mail Address: *

Phone Number: *

State Where You Live: *

Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

City Where You Need an Attorney: *

Do you have a current claim filed with: *

None Dow Corning Trust MDL 926

If you selected Dow Corning Trust or MDL 926 above, please enter the date of filing. *

Have you received a deficiency notice?

Yes
No

What are your current disease symptoms or diagnosis?

CAPTCHA Code: *

Since their introduction in 1962, silicone breast implants have been surgically emplaced in an estimated two million American women. Some women get them as part of breast reconstruction therapy following mastectomy for breast cancer, but the majority get them because they want larger breasts

There are a number of Manufacturers  who produce Breast Implants and are a part of the Silicone Breast Implant Lawsuits.

Dow Corning was one of the leaders in the production of Silicone Breast Implants.

Dow Corning Corporation was incorporated in 1943 as a joint venture of Corning Class (now Corning Incorporated) and Dow Chemical to develop, produce and market silicones. Corning, Inc. provided the silicone technology and Dow Chemical provided the manufacturing processes. Silicone is a man-made product that is formed from quartz rock, a form of silica.

In 1991, Dow Corning manufactured an sold more that 4,500 silicone-based products to 45,000 customers worldwide, and was considered a leader in the industry. About 1% of total sales in 1991 came from silicone breast implant product.

Other Manufacturers of Silicone Breast Implants include:

• Dow Corning,
• Heyer Schulte,
• American Hospital Supply,
• Natural Y,
• Surgitek,
• Replicon,
• Mentor,
• Cui,
• Bioplasty,
• Brystol Meyer Squibb,
• Medical Engineering,
• McGhan Medical,
• 3M,
• McGhan,
• Dow Corning,
• Baxter Health Care,

In the U.S the implants sold by Allergan Inc. and Johnson & Johnson's unit Mentor were huge.   Allergan’s implant business totaled about $300 million in sales for 2010.

The current claims offices offering settlements include: Dow Corning Corporation, Baxter Health Care, Bristol Meyer Squibb, 3M Corporation, McGhan, Mentor, CUI, and Bioplasty.

If you are ill and have been previously implanted with a silicone breast implant by one  of the manufacturers listed above you may be entitled to receive a settlement from the claims offices. Contact the Breast Implant Helpline and speak to a Medical social worker and a female breast implant lawyer.

Some of the brand names of eligible breast implants in the RSP are: Heyer-Schulte, American Hospital Supply, Natural Y, Surgitek, Replicon, Natural Y, MEC or Medical Engineering, all polyurethane-covered breast implants, McGhan Medical, and 3M/McGhan.

In November of  1991
The FDA brought  together its General and Plastic Surgery Devices Panel to review all of the safety data from the manufacturers' PMA's. The purpose of the panel was to advise FDA as to what they could tell the public about the safety and effectiveness of the silicone breast implants based on the PMA's. The panel was composed of a broad range of experts, including representatives from the fields of plastic surgery, oncology, epidemiology, internal medicine, immunology, radiology, pathology, gynecology, toxicology, sociology, biomaterials and psychology, as well as industry and consumer groups. The panel hearing rejected the data from Dow Corning, Mentor, McGhan, and Bioplasty, concluding there is not sufficient data about the risks and benefits of the devices. The panel recommended the devices stay on the market temporarily and with limited access. The need for more safety data was stressed.